Although the effect of specific TP53 mutation subtypes on prognosis is not fully agreed upon, the co-occurrence of TP53 and EGFR mutations generally decreases the efficacy of EGFR-TKIs in NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.